Lhermitte sign after chemo-IMRT of head-and-neck cancer: incidence, doses, and potential mechanisms

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1528-33. doi: 10.1016/j.ijrobp.2011.10.052. Epub 2012 Jan 26.

Abstract

Purpose: We have observed a higher rate of Lhermitte sign (LS) after chemo-intensity-modulated radiotherapy (IMRT) of head-and-neck cancer than the published rates after conventional radiotherapy. We hypothesized that the inhomogeneous spinal cord dose distributions produced by IMRT caused a "bath-and-shower" effect, characterized by low doses in the vicinity of high doses, reducing spinal cord tolerance.

Methods and materials: Seventy-three patients with squamous cell carcinoma of the oropharynx participated in a prospective study of IMRT concurrent with weekly carboplatin and paclitaxel. Of these, 15 (21%) reported LS during at least 2 consecutive follow-up visits. Mean dose, maximum dose, and partial volume and absolute volume (in milliliters) of spinal cord receiving specified doses (≥10 Gy, ≥20 Gy, ≥30 Gy, and ≥40 Gy), as well as the pattern of dose distributions at the "anatomic" spinal cord (from the base of the skull to the aortic arch) and "plan-related" spinal cord (from the top through the bottom of the planning target volumes), were compared between LS patients and 34 non-LS patients.

Results: LS patients had significantly higher spinal cord mean doses, V(30), V(40), and absolute volumes receiving 30 Gy or more and 40 Gy or more compared with the non-LS patients (p < 0.05). The strongest predictors of LS were higher V(40) and higher cord volumes receiving 40 Gy or more (p ≤ 0.007). There was no evidence of larger spinal cord volumes receiving low doses in the vicinity of higher doses (bath-and-shower effect) in LS compared with non-LS patients.

Conclusions: Greater mean dose, V(30), V(40), and cord volumes receiving 30 Gy or more and 40 Gy or more characterized LS compared with non-LS patients. Bath-and-shower effects could not be validated in this study as a potential contributor to LS. The higher-than-expected rates of LS may be because of the specific concurrent chemotherapy agents or more accurate identification of LS in the setting of a prospective study.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carboplatin / administration & dosage
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / therapy*
  • Chemoradiotherapy / methods*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Oropharyngeal Neoplasms / pathology
  • Oropharyngeal Neoplasms / therapy*
  • Paclitaxel / administration & dosage
  • Prospective Studies
  • Radiation Injuries / diagnostic imaging
  • Radiation Tolerance
  • Radiography
  • Radiotherapy Dosage
  • Radiotherapy, Intensity-Modulated / adverse effects
  • Radiotherapy, Intensity-Modulated / methods*
  • Spinal Cord / diagnostic imaging
  • Spinal Cord / radiation effects*

Substances

  • Carboplatin
  • Paclitaxel